Literature DB >> 32875518

Clinical risk factors related to treatment failure in Mycobacterium abscessus lung disease.

Keiji Fujiwara1, Koji Furuuchi1, Akio Aono2, Fumiko Uesugi1, Tatsuya Shirai1,3, Keitaro Nakamoto1,3, Takafumi Shimada4, Fumi Mochizuki4, Yoshiaki Tanaka1, Hiroaki Iijima4, Takashi Yoshiyama1, Yuji Shiraishi1, Atsuyuki Kurashima1, Ken Ohta1, Satoshi Mitarai2, Kozo Morimoto5,6.   

Abstract

The clinical importance of Mycobacterium abscessus subsp. abscessus (M. abscessus) lung disease has been increasing, but few studies have assessed the clinical characteristics associated with the treatment outcome. We retrospectively analyzed 75 consecutive patients with M. abscessus lung disease diagnosed at a tertiary hospital from January 2004 to April 2018. Among 52 patients with sufficient clinical data, 19 patients (42.2%) achieved treatment success. Compared with 26 (57.8%) patients in the treatment failure group, body mass index (BMI) (19.8 vs 17.5 kg/m2, P = 0.022), previous nontuberculous mycobacterial (NTM) lung disease (26.3% vs 61.5%, P = 0.034), the presence of cavitary lesions (31.6% vs 69.2%, P = 0.017), and the bronchiectasis score (3.0 vs 5.0, P = 0.003) were significantly different in the treatment success group. Multivariate analysis showed that age (adjusted hazard ratio (aHR), 0.94; 95% confidence interval (CI), 0.90 to 0.99; P = 0.010), the presence of cavitary lesions (aHR, 0.34; 95% CI, 0.12 to 0.94; P = 0.039), and previous NTM lung disease (aHR, 0.28; 95% CI, 0.09 to 0.86; P = 0.026) were negatively associated with treatment success. This is the first study to show that previous NTM lung disease might be a clinically important factor related to unfavorable treatment outcomes in M. abscessus lung disease patients. To increase our understanding the characteristics of M. abscessus lung disease, this factor should be independently analyzed in future research.

Entities:  

Keywords:  Cavity; Lung disease; Mycobacterium abscessus; Treatment outcomes

Mesh:

Year:  2020        PMID: 32875518     DOI: 10.1007/s10096-020-04026-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  30 in total

Review 1.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

2.  M ycobacterium abscessus pulmonary disease: individual patient data meta-analysis.

Authors:  Nakwon Kwak; Margareth Pretti Dalcolmo; Charles L Daley; Geoffrey Eather; Regina Gayoso; Naoki Hasegawa; Byung Woo Jhun; Won-Jung Koh; Ho Namkoong; Jimyung Park; Rachel Thomson; Jakko van Ingen; Sanne M H Zweijpfenning; Jae-Joon Yim
Journal:  Eur Respir J       Date:  2019-07-11       Impact factor: 16.671

Review 3.  British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).

Authors:  Charles S Haworth; John Banks; Toby Capstick; Andrew J Fisher; Thomas Gorsuch; Ian F Laurenson; Andrew Leitch; Michael R Loebinger; Heather J Milburn; Mark Nightingale; Peter Ormerod; Delane Shingadia; David Smith; Nuala Whitehead; Robert Wilson; R Andres Floto
Journal:  Thorax       Date:  2017-11       Impact factor: 9.139

4.  Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease.

Authors:  Won-Jung Koh; Byeong-Ho Jeong; Su-Young Kim; Kyeongman Jeon; Kyoung Un Park; Byung Woo Jhun; Hyun Lee; Hye Yun Park; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Seung-Heon Lee; Chang Ki Kim; Sung Jae Shin; Charles L Daley; Hojoong Kim; O Jung Kwon
Journal:  Clin Infect Dis       Date:  2016-11-10       Impact factor: 9.079

5.  Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus.

Authors:  Won-Jung Koh; Kyeongman Jeon; Nam Yong Lee; Bum-Joon Kim; Yoon-Hoh Kook; Seung-Heon Lee; Young Kil Park; Chang Ki Kim; Sung Jae Shin; Gwen A Huitt; Charles L Daley; O Jung Kwon
Journal:  Am J Respir Crit Care Med       Date:  2010-09-10       Impact factor: 21.405

6.  Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing.

Authors:  Sylvaine Bastian; Nicolas Veziris; Anne-Laure Roux; Florence Brossier; Jean-Louis Gaillard; Vincent Jarlier; Emmanuelle Cambau
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

7.  Further isolation of Mycobacterium abscessus subsp. abscessus and subsp. bolletii in different regions of Japan and susceptibility of these isolates to antimicrobial agents.

Authors:  Shiomi Yoshida; Kazunari Tsuyuguchi; Katsuhiro Suzuki; Motohisa Tomita; Masaji Okada; Seiji Hayashi; Tomotada Iwamoto; Hajime Saito
Journal:  Int J Antimicrob Agents       Date:  2013-07-11       Impact factor: 5.283

8.  A Laboratory-based Analysis of Nontuberculous Mycobacterial Lung Disease in Japan from 2012 to 2013.

Authors:  Kozo Morimoto; Naoki Hasegawa; Kiyohiko Izumi; Ho Namkoong; Kazuhiro Uchimura; Takashi Yoshiyama; Yoshihiko Hoshino; Atsuyuki Kurashima; Jun Sokunaga; Shunsuke Shibuya; Masahiro Shimojima; Manabu Ato; Satoshi Mitarai
Journal:  Ann Am Thorac Soc       Date:  2017-01

9.  Utility of sequencing the erm(41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs.

Authors:  Barbara A Brown-Elliott; Sruthi Vasireddy; Ravikiran Vasireddy; Elena Iakhiaeva; Susan T Howard; Kevin Nash; Nicholas Parodi; Anita Strong; Martha Gee; Terry Smith; Richard J Wallace
Journal:  J Clin Microbiol       Date:  2015-02-04       Impact factor: 5.948

10.  Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence.

Authors:  Jotam G Pasipanodya; Deborah Ogbonna; Beatriz E Ferro; Gesham Magombedze; Shashikant Srivastava; Devyani Deshpande; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

View more
  4 in total

1.  Factors Associated with Treatment Outcome in Patients with Nontuberculous Mycobacterial Pulmonary Disease: A Large Population-Based Retrospective Cohort Study in Shanghai.

Authors:  Li-Ping Cheng; Shan-Hao Chen; Hai Lou; Xu-Wei Gui; Xiao-Na Shen; Jie Cao; Wei Sha; Qin Sun
Journal:  Trop Med Infect Dis       Date:  2022-02-15

Review 2.  Incidence of Nontuberculous Mycobacterial Pulmonary Infection, by Ethnic Group, Hawaii, USA, 2005-2019.

Authors:  Rebekah A Blakney; Emily E Ricotta; Timothy B Frankland; Stacey Honda; Adrian Zelazny; Katrin D Mayer-Barber; Samantha G Dean; Dean Follmann; Kenneth N Olivier; Yihe G Daida; D Rebecca Prevots
Journal:  Emerg Infect Dis       Date:  2022-08       Impact factor: 16.126

Review 3.  Anti-Mycobacterial Drug Resistance in Japan: How to Approach This Problem?

Authors:  Keisuke Kamada; Satoshi Mitarai
Journal:  Antibiotics (Basel)       Date:  2021-12-24

4.  The 6-minute walk test predicts mortality in a pulmonary nontuberculous mycobacteria-predominant bronchiectasis cohort.

Authors:  Rebekah A Blakney; Emily E Ricotta; Dean Follmann; Jessica Drew; Kelly A Carey; Lisa N Glass; Chevalia Robinson; Sandra MacDonald; Pamela J McShane; Kenneth N Olivier; Kevin Fennelly; D Rebecca Prevots
Journal:  BMC Infect Dis       Date:  2022-01-21       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.